T37.2X5
Adverse effect of antimalarials and drugs acting on other blood protozoa
Clinical Classification Guidelines
Medical Intelligence & Overview
ICD-10 code T37.2X5 pertains to adverse effects caused by antimalarial medications and other drugs that target blood protozoa. These medications are crucial in treating protozoal infections, but they can sometimes lead to unwanted side effects. Recognizing and understanding these effects can help patients and healthcare providers manage and respond to adverse reactions more effectively.
Causes & Symptoms
Clinical Causes: Use of antimalarial drugs such as chloroquine, hydroxychloroquine, or mefloquine Administration of drugs targeting blood protozoa like pentamidine or primaquine Combination therapy involving multiple antiprotozoal medications High or prolonged dosage of antimalarial or protozoa-acting drugs Individual sensitivity or allergy to specific medication ingredients
Key Symptoms: Gastrointestinal issues such as nausea, vomiting, or abdominal pain Neurological symptoms including dizziness, headaches, or tremors Visual disturbances like blurred vision or photophobia Skin reactions such as rashes or itching Hematological effects including anemia, leukopenia, or thrombocytopenia Muscle weakness or fatigue In rare cases, liver or kidney function impairment
Diagnostic & Treatment
Diagnosis Path: Diagnosing adverse effects from antimalarial and protozoa drugs involves a thorough review of the patient's medication history, clinical examination, and laboratory tests. Blood tests may reveal hematological changes, liver function tests assess organ impact, and imaging studies might be necessary if organ toxicity is suspected. Monitoring is essential during treatment, especially for patients on long-term or high-dose therapies.
Treatment Protocols: Managing adverse effects typically involves discontinuing the offending medication, providing supportive care, and addressing specific symptoms. In cases of severe reactions, hospitalization may be required. Alternative medications might be considered to treat the primary infection while minimizing side effects. Regular monitoring and follow-up are important to ensure recovery and prevent further complications.
Clinical Advice & FAQs
Billing Guidance
Is T37.2X5 a billable ICD-10 code?
Yes, T37.2X5 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report T37.2X5?
Clinical documentation must specify the nature of Adverse effect of antimalarials and drugs acting on other blood protozoa and any associated comorbidities for accurate reporting.
Cite this Clinical Reference